251 related articles for article (PubMed ID: 2503714)
1. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. I. Macrophage-mediated tumor cell lysis.
Geetha B; Sodhi A
Nat Immun Cell Growth Regul; 1989; 8(2):100-7. PubMed ID: 2503714
[TBL] [Abstract][Full Text] [Related]
2. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. II. Production of H2O2, O2- and interleukin-1.
Sodhi A; Geetha B
Nat Immun Cell Growth Regul; 1989; 8(2):108-16. PubMed ID: 2548090
[TBL] [Abstract][Full Text] [Related]
3. Effect of cisplatin and other biological response modifiers on the activity of lysozyme, plasminogen activator and 5' nucleotidase by murine macrophages in vitro.
Geetha B; Sodhi A
Biochem Int; 1990 Dec; 22(6):1103-14. PubMed ID: 2128598
[TBL] [Abstract][Full Text] [Related]
4. Production of tumor necrosis factor by rIFN-gamma-primed C3H/HeJ (Lpsd) macrophages requires the presence of lipid A-associated proteins.
Hogan MM; Vogel SN
J Immunol; 1988 Dec; 141(12):4196-202. PubMed ID: 3143760
[TBL] [Abstract][Full Text] [Related]
5. Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages.
Drapier JC; Wietzerbin J; Hibbs JB
Eur J Immunol; 1988 Oct; 18(10):1587-92. PubMed ID: 3142779
[TBL] [Abstract][Full Text] [Related]
6. Studies on the release of interleukin-1 (IL-1), tumor necrosis factor (TNF) and lysozyme from human non-adherent mononuclear cells (nMNC) in vitro after treatment with cisplatin and other biological response modifiers.
Sodhi A; Pai K
Neoplasma; 1992; 39(4):211-7. PubMed ID: 1436230
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the priming effect of human interferon-gamma, -alpha, and -beta on synergism with muramyl dipeptide analog for anti-tumor expression of human blood monocytes.
Utsugi T; Sone S
J Immunol; 1986 Feb; 136(3):1117-22. PubMed ID: 3079797
[TBL] [Abstract][Full Text] [Related]
8. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
9. Effect of cisplatin, rIFN-Y, LPS and MDP on release of H2O2, O2- and lysozyme from human monocytes in vitro.
Pai K; Sodhi A
Indian J Exp Biol; 1991 Oct; 29(10):910-5. PubMed ID: 1667647
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
11. Lipid A-associated proteins provide an alternate "second signal" in the activation of recombinant interferon-gamma-primed, C3H/HeJ macrophages to a fully tumoricidal state.
Hogan MM; Vogel SN
J Immunol; 1987 Dec; 139(11):3697-702. PubMed ID: 3119714
[TBL] [Abstract][Full Text] [Related]
12. Augmentation by priming with interferon-gamma of the binding of a muramyl dipeptide derivative to macrophages resulting in synergistic macrophage activation.
Nagao S; Sato K; Osada Y
Jpn J Cancer Res; 1987 Jan; 78(1):80-6. PubMed ID: 3102442
[TBL] [Abstract][Full Text] [Related]
13. In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide.
Daemen T; Veninga A; Roerdink FH; Scherphof GL
Cancer Res; 1986 Sep; 46(9):4330-5. PubMed ID: 3731091
[TBL] [Abstract][Full Text] [Related]
14. Induction of membrane-associated interleukin 1 alpha (IL-1 alpha) by synergistic activation of human blood monocytes with interferon gamma and muramyl dipeptide analog.
Okubo A; Sone S; Tanaka M; Fukuta K; Inamura N; Nakanishi M; Maeda K; Yanagawa H; Nishioka Y; Yamashita C
Tokushima J Exp Med; 1989 Dec; 36(3-4):97-105. PubMed ID: 2484023
[TBL] [Abstract][Full Text] [Related]
15. Synergistic generation of tumoricidal macrophages by muroctasin and interferon-gamma.
Nagao S; Sato K; Osada Y
Arzneimittelforschung; 1988 Jul; 38(7A):999-1002. PubMed ID: 3142490
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of liposome-incorporation on liver macrophage activating potencies of rough lipopolysaccharide, lipid A, and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes.
Daemen T; Veninga A; Dijkstra J; Scherphof G
J Immunol; 1989 Apr; 142(7):2469-74. PubMed ID: 2926140
[TBL] [Abstract][Full Text] [Related]
17. The activation of tumoricidal properties in macrophages of endotoxin responder and nonresponder mice by liposome-encapsulated immunomodulators.
Fogler WE; Talmadge JE; Fidler IJ
J Reticuloendothel Soc; 1983 Mar; 33(3):165-74. PubMed ID: 6834360
[TBL] [Abstract][Full Text] [Related]
18. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
19. Effect of allogenic Dalton's lymphoma cells on the activation of murine peritoneal macrophages to tumoricidal state by cisplatin and lipopolysaccharide (LPS).
Singh SM; Singh RK; Sodhi A
Neoplasma; 1992; 39(3):151-5. PubMed ID: 1528319
[TBL] [Abstract][Full Text] [Related]
20. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
